U.S. pharma huge copyright scrapped two experimental weight loss tablets final calendar year—a once-day by day tablet, lotiglipron, because of elevated liver enzymes in addition to a 2 times-each day pill, danuglipron, because of potent Unwanted effects—but CEO Albert Bourla has reported the company is decided to “Engage in and gain” during